99 related articles for article (PubMed ID: 20129011)
1. Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine.
de Lucena D; Fernandes BS; Kunz M; Fries GR; Stertz L; Aguiar B; Pfaffenseller B; Gama CS
J Clin Psychiatry; 2010 Jan; 71(1):91-2. PubMed ID: 20129011
[No Abstract] [Full Text] [Related]
2. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
Miodownik C; Maayan R; Ratner Y; Lerner V; Pintov L; Mar M; Weizman A; Ritsner MS
Clin Neuropharmacol; 2011; 34(4):155-60. PubMed ID: 21617527
[TBL] [Abstract][Full Text] [Related]
4. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
5. Memantine-associated reversal of clozapine-induced weight gain.
Schaefer M; Leopold K; Hinzpeter A; Heinz A; Krebs M
Pharmacopsychiatry; 2007 Jul; 40(4):149-51. PubMed ID: 17694477
[TBL] [Abstract][Full Text] [Related]
6. Clozapine alone versus clozapine and risperidone with refractory schizophrenia.
Honer WG; Thornton AE; Chen EY; Chan RC; Wong JO; Bergmann A; Falkai P; Pomarol-Clotet E; McKenna PJ; Stip E; Williams R; MacEwan GW; Wasan K; Procyshyn R;
N Engl J Med; 2006 Feb; 354(5):472-82. PubMed ID: 16452559
[TBL] [Abstract][Full Text] [Related]
7. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
8. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics.
Grillo RW; Ottoni GL; Leke R; Souza DO; Portela LV; Lara DR
J Psychiatr Res; 2007; 41(1-2):31-5. PubMed ID: 16546213
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine.
Yamamori H; Hashimoto R; Ishima T; Kishi F; Yasuda Y; Ohi K; Fujimoto M; Umeda-Yano S; Ito A; Hashimoto K; Takeda M
Neurosci Lett; 2013 Nov; 556():37-41. PubMed ID: 24141084
[TBL] [Abstract][Full Text] [Related]
10. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
[TBL] [Abstract][Full Text] [Related]
11. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation.
Pedrini M; Chendo I; Grande I; Lobato MI; Belmonte-de-Abreu PS; Lersch C; Walz J; Kauer-Sant'anna M; Kapczinski F; Gama CS
Neurosci Lett; 2011 Mar; 491(3):207-10. PubMed ID: 21256922
[TBL] [Abstract][Full Text] [Related]
12. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment.
Pirildar S; Gönül AS; Taneli F; Akdeniz F
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):709-13. PubMed ID: 15276697
[TBL] [Abstract][Full Text] [Related]
13. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
14. Changes in verbal learning of patients with schizophrenia: Results from a randomized, double-blind, placebo-controlled trial of amantadine adjunctive to antipsychotics.
Czepielewski LS; Sodré L; Souza AC; Bücker J; Burke KP; Ceresér KM; Gama CS
Schizophr Res; 2015 Oct; 168(1-2):571-2. PubMed ID: 26104472
[No Abstract] [Full Text] [Related]
15. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
16. Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study.
Cerullo MA; Adler CM; Strakowski SM; Eliassen JC; Nasrallah HA; Nasrallah AT
Schizophr Res; 2007 Dec; 97(1-3):294-6. PubMed ID: 17855055
[No Abstract] [Full Text] [Related]
17. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
Feldman HH; Schmitt FA; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
[TBL] [Abstract][Full Text] [Related]
18. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.
Stryjer R; Strous R; Bar F; Shaked G; Shiloh R; Rozencwaig S; Grupper D; Buchman N; Kotler M; Rabey JM; Weizman A
Hum Psychopharmacol; 2004 Jul; 19(5):343-6. PubMed ID: 15252826
[TBL] [Abstract][Full Text] [Related]
19. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
Zink M; Mase E; Dressing H
Hum Psychopharmacol; 2004 Jun; 19(4):271-3. PubMed ID: 15181656
[TBL] [Abstract][Full Text] [Related]
20. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial.
Terevnikov V; Stenberg JH; Joffe M; Tiihonen J; Burkin M; Tchoukhine E; Joffe G
Hum Psychopharmacol; 2010 Aug; 25(6):431-8. PubMed ID: 20737516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
